Amgen (NASDAQ: AMGN) reported Q4 EPS of $4.71, $0.12 better than the analyst estimate of $4.59. Revenue for the quarter came in at $8.2 billion versus the consensus estimate of $8.12 billion.

GUIDANCE:

Amgen sees FY2024 EPS of $18.90-$20.30, versus the consensus of $19.83. Amgen sees FY2024 revenue of $32.4-33.8 million, versus the consensus of $32.5 million.

For earnings history and earnings-related data on Amgen (AMGN) click here.